It does seem out of character for Pete to say earlier in April that full year guidance remains unchanged, and then lower the guidance a few weeks later. The biggest positive was April sales are up 25% over January sales. That should have almost covered the first quarter shortfall already.
I don't buy what you are saying here. Pete wasn't born yesterday and I'm sure he did his due diligence before buying Stability. What you are saying now should have been pretty obvious in December. Besides Stability was a pretty small purchase.
You got thumbs down because of your charming personality, not because of what you mentioned. The FDA hearing has been rescheduled for September. I was hoping to hear Petit's opinion about the REGROW Act currently in the Congress. That legislation would be greatly beneficial to MiMedx.
The company has some work to do before the market buys 30% revenue growth. Quarter over quarter sales growth rates have been slowing for 9 months. I certainly wasn't expecting revenue for 2016 to be revised lower due to a 2 million dollar miss in the first quarter. The 25% increase in April sales over January sales should have covered most of that 2 million dollar miss. 250 salesmen and international sales expected in the second half of this year. Even if I assume nothing from Stability Biologics, this revised guidance for 2016 is troubling.
Pete said he didn't want to go through a miss again. Can we assume that he lowered the bar so he can go back to beating quarterly estimates again? I don't have the answer and don't want to assume anything. A couple of months ago 2016 revenue numbers seemed conservative. Last week it appeared optimistic. In early April, 2016 guidance remained unchanged. A few weeks later it is lowered. Perhaps another long term shareholder can put a more positive spin on a quarterly statement that didn't look so positive to me. I have little doubt they will meet or beat their lowered revised numbers for the rest of the year.
"This review calls into question Osiris' clinical and scientific integrity, and I believe this will ultimately be a professional embarrassment for them." Is this one of the reasons the Chief Medical Officer at Osiris was terminated recently? Was he also an embarrassment for Osiris?
I doubt it, and besides I wouldn't want to be involved with Osiris, or anybody involved with Osiris either. That company is rotten to the core.
Add bettinonthebounce to that list of aliases. It has been obvious for a long time that this pest is an Osiris shareholder and not a short seller. bettinontheloss would be more appropriate with stock picks like OSIR and ANY.
You must think a slowing at MiMedx means increased sales for Osiris. Not according to Petit. Osiris can't and won't produce financial statements so there is no way to refute what he says except with your exaggeratted and false statements. Preliminary discussions with Blue Cross/Blue Shield does not constitute completed reimbursement agreements. Actually, Osiris has no reimbursement coverage at all. MiMedx stock was dropping before Osiris released that flawed and bogus study. I would expect you can add a lawsuit from MiMedx shortly to add to your list of other lawsuits this company already has to defend.
Fraught with peril? The company could have taken a complete write off of Stability ten times over and it wouldn't equal the loss in market capitalization in the past 60 days. Nobody can really model it anymore, or how_bout_we_talk can't model it anymore? You can zero out the Stability acquisition as a total bust and the share price should be much higher than $7. Shareholders would have been much better off if Pete had consolidated the poor first quarter numbers into one press release and one earnings call in late April. In my opinion, what has hurt the stock performance most was his statement in early April that 2016 guidance was remaining unchanged. What will be most interesting to see is how prescient you are with one of your earlier comments. You said Pete has never been able to sell a company for an amount greater than its former high. In other words, you don't think he will be able to sell this company for more than $13.20. I disagree with you, but that is nothing new.
I'm coming this year too. I'd like to meet you Volstate. Any idea what you will be wearing and I'll introduce myself before the meeting. I'll be staying in the Perimeter Mall area through Friday.
"Osiris would love the publicity from a MiMedx lawsuit...bring it on."
You just got your wish Ozark. Publicity from another lawsuit that Osiris is going to lose. Unfortunately for MiMedx, I don't think Osiris will have money left to pay the judgement after paying out for the class action lawsuits and the fines the SEC will be imposing shortly.
I was thinking about taking in a game together while I am in Atlanta. Fortunately for both of us though, the Braves are playing on the road.
Friedli has taken such a miserable beating with his investment in Osiris that the timing would be good to sell that company now before they get delisted. Long term shareholders in Osiris might be disappointed though to see how little they get for that poorly run company now. There is a lot of baggage that comes along with buying Osiris here.
There looks like Big trouble with your investment in ANY. Down 10% today. Down 12% yesterday. It looks like it will be delisted shortly if it can't hold $1. There is also Big trouble with your beloved Osiris. They could be delisted too but not because the stock is below $1, or at least not yet. Do you have anymore hot picks for us where we can lose 90% or more of our money in a short period of time? I'm convinced from reading this message board that none of the shareholders here give a damn what you think.
Yesterday my wife and I accompanied a good friend to see a neurosurgeon because she will need back surgery. The surgeon was explaining the details of the surgery when he mentioned that he uses an amniotic membrane to prevent scar tissue from forming post surgery. I pressed him for details and he uses AmnioFix. He seemed surprised I had heard of it. He went on to say that he had great success with the product.
Preventing scar tissue from forming around the sciatic nerve is huge. I only wish the previous surgeon had used AmnioFix originally. The surgeon explained that the success rate for this trimming procedure drops each time the patient has surgery because the spine is left less stable, but the existing scar tissue from the first surgery is now a big part of her problem.